NIH researchers have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments. The five-drug combination targets multiple molecular pathways that diffuse large B-cell lymphoma tumors use to survive.
Friends of Cancer Research characterized postmarketing requirements and commitments over the last decade. The perspective article, titled “An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials,” provides insights into FDA’s expectations for representation of race and ethnicity in oncology clinical trials.
Researchers at the Johns Hopkins Kimmel Cancer Center’s Sol Goldman Pancreatic Cancer Research Center have developed a 3D genomic profiling technique to identify small precancerous lesions in the pancreas—called pancreatic intraepithelial neoplasias—that lead to one of the most aggressive, deadly pancreatic cancers.
NLRC5 plays a previously unknown role as an innate immune sensor, triggering cell death, according to new research from St. Jude Children’s Research Hospital. The findings, published in Cell, show how NLRC5 drives PANoptosis, a prominent type of inflammatory cell death.
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor natural killer cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from MD Anderson Cancer Center.
Fewer than one in five eligible individuals in the United States are up-to-date with recommended lung cancer screening, according to a study led by American Cancer Society researchers.
A large population-based pilot study led by researchers at the American Cancer Society and NCI shows cost discussions were infrequently documented in medical records of patients diagnosed with advanced non-small cell lung cancer and melanoma, which may hinder identifying patient financial needs and tracking outcomes of associated referrals.
A computer program based on data from nearly a half-million tissue images and powered by artificial intelligence can accurately diagnose cases of adenocarcinoma, the most common form of lung cancer, a study published June 11 in Nature Communications shows.
Investigators from UCLA Health found using artificial intelligence to help map out the boundaries of cancerous prostate tissue can significantly reduce the risk of underestimating the extent of prostate cancer—an advancement that can help ensure an accurate diagnosis, precise treatment planning and effective surgical procedures.
Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has released results from its latest clinical trial demonstrating the superior performance of their HelioLiver Dx test compared to ultrasound.
